RxDoctor Payments Data

Alber Ghobrial, MD

Psychiatry · Glen Dale, WVNPI 1447351796

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 64.4% of it on its own, with 7 other manufacturers making up the rest.

$852in general payments, 2019–2025

Across 53 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$549
  • Sunovion Pharmaceuticals Inc.$116
  • Vanda Pharmaceuticals Inc.$59
  • Johnson & Johnson$50
  • Teva Pharmaceuticals USA, Inc.$26
  • Alkermes, Inc.$25
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$852 in reported general payments places this provider in the 70th percentile of 177 psychiatry providers in West Virginia.

See all psychiatry providers in West Virginia

Medicare billing

Part B allowed, 2024
$25,235
Medicare patients
76
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$57,631
Lurasidone Hcl13$7,494
TrintellixVortioxetine Hydrobromide13$5,931
Vilazodone Hcl15$3,775
Aripiprazole67$2,794
Quetiapine Fumarate90$1,825
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$1,612
Duloxetine Hcl61$1,261
Paliperidone ErPaliperidone19$1,148
Clonazepam152$1,059
Ziprasidone Hcl12$1,049
Lamotrigine113$1,039
Bupropion XlBupropion Hcl37$898
Fluoxetine Hcl94$710
Divalproex Sodium ErDivalproex Sodium31$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$26$57,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 psychiatry providers in West Virginia.

Other psychiatry in Glen Dale

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →